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• The literature on the relationship between renal AMLs and CKD is limited, and no previous studies have explored the association between kidney involvement in TSC, health care resource utilization (HCRU), and health care costs • This study aimed to describe the association between renal AML and CKD (including the impact on HCRU and health care costs) using retrospective data from a cohort of Dutch patients with TSC treated at University Medical Center -Utrecht (UMCU), prior to the introduction of everolimus
METhODs

Data
• Database -Medical chart data from patients with TSC primarily treated at a single center in the Netherlands: UMCU -Combines patient demographic information with records from scans, surgical procedures, specialist visits, medications, and other types of HCRU -Kidney function was measured prior to any surgical procedures or embolization • Time period: January 1990 -April 2012 -While recent advances have led to the use of everolimus for the treatment of renal AML, the current study focuses on the period during which the standard of care in the Netherlands for large renal AML associated with TSC was preventative embolization 1 study design
• Retrospective, longitudinal open cohort study (see Figure 1) • Inclusion criteria 1. Diagnosis of TSC according to the revised 1998 Criteria (presence of either 2 major criteria or 1 major criteria and 2 minor criteria) 2 2. Age ≥18 years at last date of observation -All patients with TSC who visited UMCU during the observation period were provided with the option to not participate in the study. Only 2 patients opted out -No patients included in the study were treated with everolimus during the study period • Study was approved by UMCU's institutional review board -Determined from the staging criteria presented in Table 1 . The criteria, developed at UMCU, are based on 3 factors: -Number of AMLs in both kidneys -Size of the renal AMLs -Gross radiological anatomy of the kidney -Patient-years without renal AML measurement were placed in AML<3.5 cm cohort • Patients could contribute to multiple cohorts due to changes in their CKD stage and renal AML size over time • Average eGFR and the proportion of patients reaching advanced CKD stages were compared with those reported for a reference population of Dutch patients without TSC 6, 7 -Linear regression of mean eGFR on age was used to assess the age trend in mean eGFR • HCRU was measured as event counts (scans, surgery, non-surgical procedures [including embolization], specialist visits) and patient-years of treatment (medication, dialysis) • HCRU rates and health care costs (2012€) per patient per year (PPPY) were compared across cohorts -HCRU rates were compared using rate ratios (RRs) estimated by Poisson regressions -Health care costs were estimated from unit costs based on Dutch tariffs and were compared using the cost differences between cohorts 8,9
-P-values for RRs and cost differences were estimated by non-parametric bootstrap to account for the open cohort study design and non-normality of health care costs Age range depicted includes ages for which there are at least 10 patients in the current study. B. UMCU cohort of patients with TSC: Mean GFR among patients at a given age, estimated from serum creatinine levels using the CKD-EPI formula.
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Same patient may contribute multiple observations to a given age and to multiple ages. Shading depicts 95% confidence interval for the mean. C. Normal population: Based on GFR estimated from serum creatinine for Caucasian males and females using the CKD-EPI formula, reported in a 2007 population-based cross-sectional study conducted in the eastern part of the Netherlands. 6, 7 Plot depicts weighted averages of median GFR reported for males and females. Weights equal to the proportion of each gender within a given age cohort of the current study. (Table 2) • Advanced CKD stages were associated with increased age, female gender, and larger renal AML
Patient characteristics by CKD stage
• CKD was also associated numerous small AML hCRU rates by CKD stage (Figure 3) • Advanced CKD stages were associated with higher overall HCRU rates (RRs vs. stage 1 = 1.53 to 2.32, P≤0.01 for all)
• Compared with CKD stage 1, patients at CKD stage 3 had higher rates of scans, kidney surgery, non-surgical procedures, specialist visits, and medication use (RRs = 1.23 to 4.56, P≤0.01 for all)
• Patients who progressed to higher CKD stages were more likely to have undergone renal embolization -59.3% of patients underwent embolization prior to or during their time at CKD stage 3 vs. 25.4% at CKD stage 1 -More generally, the use of non-surgical procedures constituted a markedly larger share of overall HCRU among patients at CKD stages 4 and 5 compared with patients at lower CKD stages 
LIMITATIONs
• Small sample sizes for select sub-groups and missing data limit the precision and generalizability of the results and preclude more detailed analyses
• Results may understate the true extent to which age is associated with reduced kidney function due to survivor bias
• Results do not have a causal interpretation, due in part to confounding by indication
• This study was based on a single-country, single-center design
CONCLUsIONs
• Patients with TSC tend to develop kidney impairment more frequently, and at an earlier age, than patients without TSC
• CKD in patients with TSC is associated with renal AML severity, HCRU, and health care costs -CKD was associated with the presence of numerous small renal AML as well as larger renal AML -Dialysis accounted for a substantial proportion of overall health care costs in patients with TSC and advanced CKD -Preventative embolization may not be able to prevent progressive CKD in this patient population
• Impaired kidney function associated with renal AML imposes a significant burden and remains a key concern in patients with TSC -There is a need for routine kidney function monitoring and early intervention in patients with TSC -Treatments that slow the rate of kidney function decline in patients with TSC may substantially reduce the HCRU and costs associated with CKD and renal AML in this patient population
